CXCR4 拮抗劑市場：現況分析與預測（2024-2032）

預計預測期內（2024-2032 年），CXCR4 拮抗劑市場將以 12.37% 的顯著複合年增長率成長。這主要是為了增加對新進展和技術的瞭解，從而增強製藥公司正在進行的研究和開發以及 CXCR4 拮抗劑對癌症、愛滋病毒和其他慢性發炎疾病的治療開發。和市場佔有率。此外，監管機構的支持不斷增加，進一步推動了 CXCR4 拮抗劑市場的顯著成長。

依類型，市場分為 Plerixafor 和其他。普樂沙福（Plerixafor），又稱莫佐韋（Mozovir），由於在動員造血幹細胞進行移植方面有著良好的記錄，因此擁有很大的市場佔有率。建議與粒細胞集落刺激因子（G-CSF）一起使用或單獨使用，並於2008年獲得FDA批准。是多發性骨髓瘤患者的首選藥物。不過，由 BL-8040（Motixafortide）、Mavorixafor 和其他產品組成的 "其他" 部分預計未來將會成長。這是因為最近進行了涉及這些藥物的臨床試驗及其在其他治療領域的潛在應用。較新的藥物可能具有更好的療效和安全性，從而提供新的治療選擇，推動未來的市場成長。

市場依應用分為癌症、愛滋病毒、慢性發炎疾病和其他疾病。其中，腫瘤領域佔據CXCR4拮抗劑市場的最大佔有率。這項優勢的出現正值乳癌和肺癌等各類癌症的發生率不斷上升之際，CXCR4拮抗劑正被用於預防腫瘤轉移和解決與化療抗藥性相關的問題。然而，預計愛滋病毒領域將成為預測期內成長最快的領域。這一增長是由 HIV 感染發病率的不斷上升以及對結合 CXCR4 拮抗劑以優化 HIV 治療效果的 HIV 療法的持續需求所推動的。

根據分銷管道，市場分為醫院藥房、零售藥房和線上藥房。在這些細分市場中，醫院藥房佔據最大的市場佔有率，因為這些機構為醫療機構提供有價值的服務。我們供應和分發用於治療癌症患者的重要藥物，例如莫佐韋（CXCR4拮抗劑）。然而，由於消費者對便利性和移動性的偏好，線上藥局市場的價值預計未來幾年將大幅成長。新冠肺炎疫情加速了數位醫療服務的使用，並促使更多患者在線上購買藥品。

為了更瞭解CXCR4 拮抗劑（如普樂沙福）的市場滲透率，市場被細分為北美（美國、加拿大和北美其他地區）、歐洲（德國、法國、英國、西班牙、義大利和北美其他地區）。由於癌症發生率不斷增加，尤其是在中國和印度等國家，預計預測期（2024-2032 年）亞太地區將以顯著的複合年增長率增長。 CXCR4 拮抗劑市場專注於協作開發活動，以改善產品開發並帶來新藥。例如，2021年11月，和譽生物科技股份有限公司與X4 Pharmaceuticals, Inc.合作開發CXCR4拮抗劑。

參與市場的主要公司包括 Sanofi、Teva Pharmaceutical Industries Ltd.、X4 Pharmaceuticals, Inc.、BioLineRx Ltd.、Merck KGaA、GPCR Therapeutics、AdAlta Limited、Spexis Ltd.、GlycoMimetics、Abbisko Therapeutics Co. .Ltd、 ETC .Ltd、 ETC .Ltd. 。

目錄

第一章 市場介紹

• 市場定義
• 主要目的 利害關係人
• 限制

第 2 章 研究方法或假設

• 研究過程
• 研究方法
• 受訪者資料

第 3 章執行摘要

• 產業摘要
• 各細分市場的展望
  • 市場成長強勁
• 區域展望

第 4 章 市場動態

• 驅動程式
• 機會
• 阻礙因素
• 趨勢
• PESTEL 分析
• 需求方分析
• 供給面分析
  • 合作協議和協作活動
  • 投資場景

第 5 章 全球 CXCR4 拮抗劑市場收入（2022-2032）

第 6 章 市場洞察：按類型

• Plerixafor
• 其他

第 7 章市場洞察：按應用

• 癌症
• 愛滋病毒
• 慢性發炎性疾病
• 其他

第 8 章。

• 醫院藥房
• 零售藥局
• 在線

第 9 章。

• 北美洲
  • 美國
  • 加拿大
  • 其他北美地區
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 其他歐洲地區
  亞太地區
  • 中國
  • 日本
  • 印度
  • 其他亞太地區
• 世界其他地區

第 10 章 價值鏈分析

第 11 章 競爭格局

• 競爭資訊中心
• 競爭市場定位分析
• 波特五力分析

第 12 章 公司簡介

• Sanofi
  • 公司概況
  • 關鍵財務訊息
  • SWOT 分析
  • 產品組合
  • 最新趨勢
• Teva Pharmaceutical Industries Ltd.
• X4 Pharmaceuticals, Inc.
• BioLineRx Ltd.
• Merck KGaA
• GPCR Therapeutics
• AdAlta Limited
• Spexis Ltd.
• GlycoMimetics
• Abbisko Therapeutics Co. Ltd.

第 13 章 縮寫與先決條件

第 14 章附錄

CXCR4 antagonists are substances that bind to the CXCR4 receptor, a G-protein subfamily that is involved in a number of cellular functions for instance, inflammation and metastasis. As CXCR4 antagonists occlude this receptor, they lock out the interaction with its ligand CXCL12 which plays a role in cell migration and metastasis. This mechanism is especially noteworthy in oncology since the focalization through CXCR4 promotes the migration of cancer cells to appropriate niches. To date, the most well-known CXCR4 inhibitor is Plerixafor (AMD3100), which was approved by the FDA in 2008 to stimulate the mobilization of hematopoietic stem cells in patients preparing to undergo autologous transplant. Other candidates in the same class such as BL-8040 have been also tested in clinical trials for different types of cancer including leukemia and pancreatic cancer. These antagonists not only imbalanced tumor-stroma relationships but also promoted tumor immune therapy by attracting immune cells inside the tumor tissue. Newer emphasis has been directed towards novel non-peptide CXCR4 antagonists and their role in the management of cancers through targeting of anti-apoptotic CXCL12/CXCR4 signaling axis and reduction in metastasis and better therapeutic response against chemo-resistant tumors.

The CXCR4 Antagonist Market is expected to grow with a significant CAGR of 12.37% during the forecast period (2024-2032). This is mainly due to the continuous research and development by pharmaceutical companies, along with increased mergers and acquisitions activities to boost their capacities and shares to increase their knowledge of new advancements and technologies, which can enhance the development of CXCR4 antagonists' therapeutics for cancer, HIV and other chronic inflammatory diseases. Moreover, the growing support from the regulatory bodies is further assisting in the significant growth of the CXCR4 antagonist market.

Depending on the Type the market is divided into two types namely the Plerixafor and Others. Plerixafor, which is also known as Mozobil, occupies a large market share because of its proven performance in the mobilization of hematopoietic stem cells for transplantation. Recommended for use with or without the support of granulocyte colony stimulating factor (G-CSF) it received FDA approval in 2008, and it is the first choice for patients with lymphoma or multiple myeloma who do not receive adequate mobilization by G-CSF alone. However, the "Others" segment, comprising BL-8040 (Motixafortide), Mavorixafor, and other products is predicted to grow in the future, and this is attributed to recent clinical trials involving the drugs and their potential application in other therapeutical areas. Newer agents may be associated with better efficacy or safety and hence provide additional therapeutic choices, to fuel market growth in the future.

Based on the Application, the market is segmented into cancer, HIV, chronic inflammatory disease, and others. Out of these cancer segments hold the maximum share in the CXCR4 antagonist market. This dominance is due to the rising prevalence of different types of cancer including breast and lung cancer, which has the use of CXCR4 antagonists that prevent metastasis of tumors and tackle issues related to chemotherapy resistance. However, the HIV segment is expected to be the fastest-growing segment in the forecasted period. This growth is attributed to the increasing incidence of HIV infections and the continued demand for HIV treatments that incorporate CXCR4 antagonists to optimize the outcomes of HIV treatment.

According to the distribution channel, the market is categorized into hospital pharmacies, retail pharmacies, and online segments. Out of these segments, the hospital pharmacy has taken the largest market share because these institutions offer invaluable services to healthcare organizations. They offer and dispense the needed medicine such as Mozobil (CXCR4 antagonist), which is important in treating patients with cancer. However, it is predicted that the value of the online pharmacy segment will rise significantly in the future due to customer orientation toward convenience and mobility. The outbreak of COVID-19 advanced the utilization of digital health services, pushing additional patients to purchase medications online.

For a better understanding of the market penetration of CXCR4 antagonists such as Plerixafor, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, France, U.K., Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. Asia-Pacific is expected to grow with a significant CAGR in the forecast period (2024-2032) owing to the growing incidence of cancer, especially in countries like China and India. The emphasis is made on the development of collaboration activities to improve the product development in the CXCR4 antagonist market for bringing new drug. For instance, in November 2021, Abbisko Therapeutics Co. Ltd., which is a China-based biopharmaceutical company, Joined hands with X4 Pharmaceuticals, Inc. for the development of CXCR4 antagonists.

Some of the major players operating in the market include Sanofi, Teva Pharmaceutical Industries Ltd., X4 Pharmaceuticals, Inc., BioLineRx Ltd., Merck KGaA, GPCR Therapeutics, AdAlta Limited, Spexis Ltd., GlycoMimetics, Abbisko Therapeutics Co. Ltd.

TABLE OF CONTENTS

1.MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2.RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the CXCR4 Antagonist Market
• 2.2. Research Methodology of the CXCR4 Antagonist Market
• 2.3. Respondent Profile

3.EXECUTIVE SUMMARY

• 3.1. Industry Synopsis
• 3.2. Segmental Outlook
  • 3.2.1. Market Growth Intensity
• 3.3. Regional Outlook

4.MARKET DYNAMICS

• 4.1. Drivers
• 4.2. Opportunity
• 4.3. Restraints
• 4.4. Trends
• 4.5. PESTEL Analysis
• 4.6. Demand Side Analysis
• 4.7. Supply Side Analysis
  • 4.7.1. Partnership agreements and collaboration activities
  • 4.7.2. Investment Scenario

5.GLOBAL CXCR4 ANTAGONIST MARKET REVENUE (USD MN), 2022-2032F

6.MARKET INSIGHTS BY TYPE

• 6.1. Plerixafor
• 6.2. Others

7.MARKET INSIGHTS BY APPLICATION

• 7.1. Cancer
• 7.2. HIV
• 7.3. Chronic Inflammatory Disease
• 7.4. Others

8.MARKET INSIGHTS BY DISTRIBUTION CHANNEL

• 8.1. Hospital Pharmacies
• 8.2. Retail Pharmacies
• 8.3. Online

9.MARKET INSIGHTS BY REGION

• 9.1. North America
  • 9.1.1. U.S.
  • 9.1.2. Canada
  • 9.1.3. Rest of North America
• 9.2. Europe
  • 9.2.1. Germany
  • 9.2.2. U.K.
  • 9.2.3. France
  • 9.2.4. Italy
  • 9.2.5. Spain
  • 9.2.6. Rest of Europe
• 9.3. Asia-Pacific
  • 9.3.1. China
  • 9.3.2. Japan
  • 9.3.3. India
  • 9.3.4. Rest of Asia-Pacific
• 9.4. Rest of World

10.VALUE CHAIN ANALYSIS

11.COMPETITIVE LANDSCAPE

• 11.1. Competition Dashboard
• 11.2. Competitor Market Positioning Analysis
• 11.3. Porter Five Forces Analysis

12.COMPANY PROFILES

• 12.1. Sanofi
  • 12.1.1. Company Overview
  • 12.1.2. Key Financials
  • 12.1.3. SWOT Analysis
  • 12.1.4. Product Portfolio
  • 12.1.5. Recent Developments
• 12.2. Teva Pharmaceutical Industries Ltd.
• 12.3. X4 Pharmaceuticals, Inc.
• 12.4. BioLineRx Ltd.
• 12.5. Merck KGaA
• 12.6. GPCR Therapeutics
• 12.7. AdAlta Limited
• 12.8. Spexis Ltd.
• 12.9. GlycoMimetics
• 12.10. Abbisko Therapeutics Co. Ltd.

13.ACRONYMS & ASSUMPTION

14.ANNEXURE